Author: itembalabantu
-
Mechanism-Encoded Prediction of Prime Editing: What OptiPrime’s Ablations Actually Prove, and What Remains Unconfirmed
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The Nature Biotechnology version of the paper discussed here is paywalled and was not accessed by this outlet. Everything below marked “confirmed” was verified directly against the bioRxiv preprint (submitted 2026-02-20), which the…
-
Is Retrieval All You Need? Depends How You Score It — An In Silico Preprint Recalibrates Protein-Generator Novelty Claims
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The paper discussed here is an unpeer-reviewed arXiv preprint (submitted 2026-08-11), and every comparison in it — including the one summarized below — is an in silico structural alignment and scoring exercise. No…
-
A genome language model designed working bacteriophages — and a second paper the same week shows the capability is not uniform
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. A paper in Science (6 August 2026) reports the first generative design of complete bacteriophage genomes using genome language models. Working from the phage ΦX174 as…
-
Three levers on fault-tolerance overhead — and why they sit on three different evidence tiers
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. Fault-tolerant quantum computing has one dominant cost: the number of physical qubits and operations needed per useful logical qubit. Four results from 2026 push on that cost from three…
-
A concept-bottleneck AI predicts immunotherapy response across cancers — but every result is retrospective, and the survival win rests on one sponsor’s own trial
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. The 30-second version What. A Harvard (Zitnik lab) and Roche team published COMPASS in Nature Medicine (2026-07-03, doi:10.1038/s41591-026-04502-7): a lightweight (~1.02M-parameter) “concept-bottleneck” transformer that reads a tumour’s bulk RNA-seq and predicts response to…
-
Inertial confinement and the alternative-concept boom — NIF’s ignition record (target gain 4.13, 2025) is real, but NIF is a weapons-physics facility (negative wall-plug, 2–3 shots/day), not a power path, and the private alternatives each carry an unproven core
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. All temperatures, pressures, gains and timelines are attributed to the sponsoring laboratory or company; many are company announcements or trade-press reports rather than peer-reviewed data (noted inline). A “target gain” (a plasma-side ratio)…
